Unknown Manufacturer
JUV-161 is Juvena Therapeutics' first-in-class regenerative biologic, currently enrolling subjects in a Phase 2a atrophy study. It holds FDA Orphan Drug Designation for myotonic dystrophy and was discovered using JuvNET, Juvena's proprietary AI-enabled platform for mapping the therapeutic potential of stem cell-secreted proteins.
JUV-161 is Juvena Therapeutics' first-in-class regenerative biologic, currently enrolling subjects in a Phase 2a atrophy study. It holds FDA Orphan Drug Designation for myotonic dystrophy and was discovered using JuvNET, Juvena's proprietary AI-enabled platform for mapping the therapeutic potential of stem cell-secreted proteins.
1 associated conditions
